Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Rechallenge in Metastatic Colorectal Cancer
NCT03524820Phase 2Terminated
- Sponsor
- Hadassah Medical Organization
- Start
- Oct 2017
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Hadassah Medical Organization. Primary endpoint: Response to treatment at 5 years. Started Oct 2017; status: terminated.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03524820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524820.